The nation of Zimbabwe has turned down a substantial American health deal worth $367m (272 million pounds) over five years due to Washington's request for sensitive information.
The decision became public after a internal memorandum dated December was disclosed, which showed President Emmerson Mnangagwa believed the deal was "unbalanced".
A government spokesman has since explained that the US was requesting genetic material for scientific study and commercial gain but was not willing to guarantee the benefits from future vaccines.
"We are forced to start the challenging and unfortunate process of winding down our health assistance in Zimbabwe," stated American envoy to Zimbabwe Pamela Tremont publicly.
Her embassy indicated the US had provided over $1.9bn in health funding to Zimbabwe over the last twenty years.
A medical body in Zimbabwe has appealed for further dialogue to secure a deal acceptable to both sides so the country's vital HIV treatment initiative can continue.
Broader Background
Zimbabwe's decision comes after a comparable case in neighbouring Kenya, where a high court blocked a similar health funding agreement following legal challenges were raised about the safety of Kenyans' health data.
After resuming office recently, US President Donald Trump has slashed foreign aid and closed the US Agency for International Development (USAID).
The agency had administered aid for the US government, but Trump claimed its spending was "wasteful" and his government was pursuing direct bilateral deals to enhance transparency and responsibility.
According to reports, 16 African countries have so far signed similar health pacts, representing over $18.3bn of fresh investment.
Details of the Declined Agreement
This assistance for Zimbabwe was intended to supported "tackling HIV/Aids, tuberculosis, malaria, healthcare for mothers and children, and preparing for epidemics".
"We believe this cooperation might have yielded immense advantages for Zimbabwean communities, especially the 1.2 million men, women and children presently receiving HIV treatment through American-funded programmes," Tremont said.
However, official spokesman Nick Mangwana argued the arrangement was "asymmetrical".
"Our nation was requested to share its genetic material and health information over an extended period, with no corresponding assurance of benefiting from any medical innovations – such as vaccines, diagnostics, or treatments – that could be developed from that provided information," his statement read.
"In essence, our nation would supply the raw materials for medical research with no certainty that the end products would be available to our citizens if a future disease outbreak emerge."
National Interest and Global Health
He also said that the US's withdrawal from the global health body and its push of bilateral deals were disrupting frameworks already set up via the international organization.
Mangwana gave as an example its Pandemic Benefit-Sharing scheme created to deal with potential pandemics.
"This mechanism is designed to guarantee that when a country contributes its data, the benefits – including medicines and cures – are shared equitably, not commercialised solely by those with the funds to create them."
The government's concerns over the US deal "are not meant as anti-American sentiment," he added.
"We welcome continued dialogue with our US partners on how subsequent collaboration could be designed in a way that honours the sovereignty and interests of each country."
Medical Community Reaction
Medical experts expressed it understood the official position, but urged that talks must proceed since much of the nation's Aids initiatives were funded by foreign aid.
"In cases where technical issues arise, including those relating to data governance or agreement terms, these can frequently be addressed via technical clarification and negotiated safeguards," the group added.
The halted deal emphasises the complex challenges between accepting crucial foreign assistance and protecting national sovereignty in an ever more data-driven world.